ReviewFrontiers in immunology2026
Probiotics in type 1 diabetes: immunomodulatory mechanisms and the unresolved question of clinical efficacy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 Diabetes (T1D) is a common autoimmune disease worldwide, which is associated with imbalanced gut microbiota. Intestinal dysbiosis plays a key role in the pathogenesis of T1D, and it may affect immune tolerance and autoimmune responses of pancreatic islet β-cells. As a potential immunomodulator, probiotics can help restore this balance, regulate immune responses, and reduce the risk of T1D. Although probiotics offer a logical immunomodulatory strategy to restore microbial and immune homeostasis, the translational gap between robust preclinical mechanisms and inconsistent clinical outcomes remains poorly defined. This review summarizes the mechanisms of action and clinical research progress of probiotics in the immunotherapy of T1D. Firstly, it elaborates on the key pathways through which probiotics regulate the gut-immune-pancreas axis. Subsequently, it conducts a comparative analysis of important clinical trials on probiotic therapy for T1D in recent years, comparing the differences in efficacy of different intervention timings, different bacterial strains, etc., in the prevention and adjuvant treatment of T1D, and explores their relationships with patients' age, disease duration, and genetic background. Meanwhile, it points out the limitations of current research, so as to provide important references for future studies. Furthermore, this review looks forward to the future directions of probiotics in the field of T1D immunotherapy, including innovative approaches such as engineered bacteria transformation, targeted delivery, and personalized microbiota intervention. Finally, it evaluates the safety of probiotics in the treatment of T1D, aiming to explore an individualized probiotic therapy method and lay a more reliable foundation for subsequent clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.